October 2, 2021 | Targeted Therapies in Oncology

Pursuing Optimal Therapy Remains a Challenge in Indolent B-Cell Lymphoma

October 25, 2021

Clinical Articles

A significant proportion of patients worldwide live disease-free for a decade or longer following first-line therapy, with various approaches suggesting that there may be pathways to develop approaches for a cure for at least a subset of patients

High pCR Rate Shows Potential for Neoadjuvant Osimertinib in EGFR+ NSCLC

October 24, 2021

Clinical Articles

Neoadjuvant osimertinib may lead to a better mechanistic understanding of what drives incomplete response and residual disease for patients with EGFR-mutant NSCLC. according to Collin M. Blakely, MD, PhD.

Targeted Therapies in Chronic Lymphocytic Leukemia

October 19, 2021

Clinical Articles

In chronic lymphocytic leukemia management, many patients do not fall within the category to receive chemoimmunotherapy. However, for high-risk patients, targeted agents are changing the treatment landscape.